#BEGIN_DRUGCARD DB04570

# AHFS_Codes:
Not Available

# ATC_Codes:
J01DD06

# Absorption:
Rapidly absorbed after oral administration.

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
64952-97-2

# ChEBI_ID:
599928

# Chemical_Formula:
C20H20N6O9S

# Chemical_IUPAC_Name:
(6R,7R)-7-[2-carboxy-2-(4-hydroxyphenyl)acetamido]-7-methoxy-3-{[(1-methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2007-09-06 17:50:34 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Broad- spectrum beta-lactam antibiotic similar in structure to the cephalosporins except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain cephalosporins. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections. [PubChem]

# Dosage_Forms:
Not Available

# Drug_Category:
Anti-Bacterial Agents
Cephalosporins

# Drug_Interactions:
Not Available

# Drug_Reference:
3778044	Brown RB, Klar J, Lemeshow S, Teres D, Pastides H, Sands M: Enhanced bleeding with cefoxitin or moxalactam. Statistical analysis within a defined population of 1493 patients. Arch Intern Med. 1986 Nov;146(11):2159-64.
6217353	Weitekamp MR, Aber RC: Prolonged bleeding times and bleeding diathesis associated with moxalactam administration. JAMA. 1983 Jan 7;249(1):69-71.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-0.58

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Latamoxef

# HET_ID:
Not Available

# Half_Life:
1.6 hours

# InChI_Identifier:
InChI=1S/C20H20N6O9S/c1-25-19(22-23-24-25)36-8-10-7-35-18-20(34-2,17(33)26(18)13(10)16(31)32)21-14(28)12(15(29)30)9-3-5-11(27)6-4-9/h3-6,12,18,27H,7-8H2,1-2H3,(H,21,28)(H,29,30)(H,31,32)/t12?,18-,20+/m1/s1

# InChI_Key:
InChIKey=JWCSIUVGFCSJCK-CAVRMKNVSA-N

# Indication:
Latamoxef is an oxacephem antibiotic usually grouped with the cephalosporins. It is used to treat bacterial infections. Latamoxef  is primarily indicated in conditions like Bone and joint infection, GI infections, Gynecological infections, Meningitis, Respiratory tract infections, Septicaemia, Skin infections, Soft tissue infections, UTI.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D08109

# LIMS_Drug_ID:
4570

# Mechanism_Of_Action:
Penicillins acylate the penicillin-sensitive transpeptidase C-terminal domain (the penicillin-binding protein) by opening the lactam ring. This inactivation of the enzyme prevents the formation of a cross-link of two linear peptidoglycan strands, inhibiting the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that amoxicllin interferes with an autolysin inhibitor.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
520.473

# Molecular_Weight_Mono:
520.101246958

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164743144

# Pharmacology:
Latamoxef works by inhibiting bacterial cell wall biosynthesis.

# Predicted_LogP_Hydrophobicity:
0.22

# Predicted_LogS:
-2.8

# Predicted_Water_Solubility:
7.51e-01 g/l

# Primary_Accession_No:
DB04570

# Protein_Binding:
40%

# PubChem_Compound_ID:
47499

# PubChem_Substance_ID:
46505546

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[H][C@]12OCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)C(C(O)=O)C1=CC=C(O)C=C1)OC)C(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
moxalactam

# Synthesis_Reference:
Not Available

# Toxicity:
Latamoxef produces potentially life-threatening effects which include Bleeding, Hypothrombinemia, Platelet dysfunctioning. which are responsible for the discontinuation of Latamoxef therapy.
The symptomatic adverse reactions produced by Latamoxef are more or less tolerable and if they become severe, they can be treated symptomatically, these include Diarrhea, Skin rashes, Hematuria, Hyperuricemia, Pyuria, Raised serum creatinine.

# Update_Date:
2013-02-08 16:23:28 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Latamoxef

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
3918982	Labia R, Baron P, Masson JM: Binding of latamoxef (moxalactam) and its decarboxylated derivative to Escherichia coli and Pseudomonas aeruginosa penicillin-binding proteins. J Antimicrob Chemother. 1985 Jan;15(1):9-15.
9841767	Ishikawa M, Miyauchi T, Yagi K, Chikaishi H, Fukuta Y, Miyake H, Harada M, Yogita S, Tashiro S: Clinical relevance of antibiotic-induced endotoxin release in patients undergoing hepatic resection. World J Surg. 1999 Jan;23(1):75-9.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
D38161

# Drug_Target_1_GenBank_ID_Protein:
790944

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
pbpC

# Drug_Target_1_Gene_Sequence:
>2007 bp
ATGTTAAAAAAGTGTATTCTACTAGTATTTCTATGCGTCGGATTGATTGGGTTAATCGGA
TGCTCCAAAACAGATTCACCAGAGGATCGCATGGAAGCATTCGTGAAACAGTGGAACGAT
CAGCAATTCGATGACATGTATCAAAGCCTGACTAAAGATGTCAAAAAAGAAATCTCCAAA
AAAGATTTCGTCAACAGGTATAAAGCCATCTATGAGCAGGCCGGCGTAAAAAATTTGAAA
GTCACTGCGGGAGAAGTAGATAAGGACGATCAAGACAACAAGACGATGAAACATATCCCG
TATAAAGTCAGCATGAACACAAATGCCGGCAAAGTCAGCTTCAAGAATACTGCTGTGCTG
AAATTAGAAAAAACAGATGACGAGGAGTCATGGAATATAGATTGGGACCCATCGTTTATT
TTCAAGCAGCTGGCTGACGACAAAACCGTGCAAATTATGAGCATTGAACCGAAACGAGGC
CAAATTTACGATAAAAATGGAAAAGGCTTAGCCGTCAATACAGATGTTCCGGAAATTGGA
ATTGTTCCCGGAGAGCTTGGCGATAAAAAAGAGAAAGTCATAAAAGAACTCGCCAAAAAA
CTTGATTTGACTGAAGACGACATCAAGAAAAAGCTGGATCAAGGCTGGGTAAAAGACGAT
TCGTTTGTGCCGCTCAAAAAGGTCAAGCCTGACCAGGAGAAATTAGTTTCTGAAGCGACG
TCATTACAAGGCGTAACAAGAACGAATGTCAGCTCCCGCTACTATCCGTATGGCGAAAAG
ACAGCCCATTTGACAGGCTATGTCCGCGCCATTACAGCGGAAGAACTGAAGAAAAAGAAA
GAAGGAACGTACAGCGATACGTCTAACATCGGTATCGCCGGACTTGAAAATGTGTATGAA
GACAAGCTAAGAGGCACAACTGGCTGGAAAATCTACGTGCCGCAAACCGGGGAAGTCATC
GCTGAAAAGAAAGCAAAGGACGGCGAGGATCTTCACCTCACAATTGATATCAAAACGCAA
ATGAAGCTGTATGATGAACTGAAGGATGACAGCGGGGCGGCAGTCGCGCTGCAGCCGAAG
ACAGGCGAAACACTCGCCCTTGTCAGCGCGCCTTCCTACGATCCAAACGGATTTATTTTC
GGCTGGAGCGATAAGGAATGGAAAAAGCTAAACAAAGATAAAAACAATCCGTTTTCAGCG
AAATTCAATAAGACATACGCGCCAGGTTCTACCATTAAACCGATTGCGGCTGCTATTGGA
ATCAAAAACGGCACCCTTAAAGCCGATGAGAAGAAAACAATCAAAGGCAAGGAGTGGCAA
AAAGATTCAAGCTGGGGCGGCTATTCAGTGACACGTGTGTCTGAGAGACTTCAACAAGTC
GATTTGGAAAACGCCCTTATTACGTCAGACAATATTTATTTTGCCCAGAATGCGCTTGAT
ATGGGAGCGGACACCTTTACAAAAGGCTTGAAGACATTCGGTTTTTCAGAGGACGTTCCG
TACGAATTCCCGATCCAGAAATCGTCTATTGCAAATGACAAGCTTGATTCAGACATTTTG
CTTGCGGATACAGGCTACGGACAAGGGCAAATGCAAATGTCTCCGCTTCACTTGGCAACT
GCTTACACGCCATTTGTTGACAATGGAGACCTTGTCAAACCGACGCTGATCAAAAAAGAT
TCACAAACAGCTGATGTTTGGCACAAGCAAGTGGTCACGAAGGAAGGAGCGGCAGACATT
ACAAAAGGTCTGAAAGGCGTTGTGGAAGATGAGCGCGGATCAGCGTATCAGCCTGTCGTG
AAAGGAATCACAGTGGCTGGAAAAACAGGAACAGCCGAGCTGAAAACATCAAAAGATGAT
AAAGACGGCACGGAAAATGGCTGGTTTGTCGGCTACGATTACGAAAACAAAGACCTGCTT
GTCGCCATGATGATCCAAAATGTGCAGGACCGCGGCGGCAGCCACTATGTCGTTGAGAAA
GCGAAAAAGCAATTTCAATCGAATTAA

# Drug_Target_1_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_1_General_References:
3145906	Smith H, de Jong A, Bron S, Venema G: Characterization of signal-sequence-coding regions selected from the Bacillus subtilis chromosome. Gene. 1988 Oct 30;70(2):351-61.
8969502	Yamane K, Kumano M, Kurita K: The 25 degrees-36 degrees region of the Bacillus subtilis chromosome: determination of the sequence of a 146 kb segment and identification of 113 genes. Microbiology. 1996 Nov;142 ( Pt 11):3047-56.
9384377	Kunst F, Ogasawara N, Moszer I, Albertini AM, Alloni G, Azevedo V, Bertero MG, Bessieres P, Bolotin A, Borchert S, Borriss R, Boursier L, Brans A, Braun M, Brignell SC, Bron S, Brouillet S, Bruschi CV, Caldwell B, Capuano V, Carter NM, Choi SK, Codani JJ, Connerton IF, Danchin A, et al.: The complete genome sequence of the gram-positive bacterium Bacillus subtilis. Nature. 1997 Nov 20;390(6657):249-56.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
867

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
74407

# Drug_Target_1_Name:
Penicillin-binding protein 3

# Drug_Target_1_Number_of_Residues:
668

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00905	Transpeptidase
PF03717	PBP_dimer
PF05223	MecA_N

# Drug_Target_1_Protein_Sequence:
>Penicillin-binding protein 3
MLKKCILLVFLCVGLIGLIGCSKTDSPEDRMEAFVKQWNDQQFDDMYQSLTKDVKKEISK
KDFVNRYKAIYEQAGVKNLKVTAGEVDKDDQDNKTMKHIPYKVSMNTNAGKVSFKNTAVL
KLEKTDDEESWNIDWDPSFIFKQLADDKTVQIMSIEPKRGQIYDKNGKGLAVNTDVPEIG
IVPGELGDKKEKVIKELAKKLDLTEDDIKKKLDQGWVKDDSFVPLKKVKPDQEKLVSEAT
SLQGVTRTNVSSRYYPYGEKTAHLTGYVRAITAEELKKKKEGTYSDTSNIGIAGLENVYE
DKLRGTTGWKIYVPQTGEVIAEKKAKDGEDLHLTIDIKTQMKLYDELKDDSGAAVALQPK
TGETLALVSAPSYDPNGFIFGWSDKEWKKLNKDKNNPFSAKFNKTYAPGSTIKPIAAAIG
IKNGTLKADEKKTIKGKEWQKDSSWGGYSVTRVSERLQQVDLENALITSDNIYFAQNALD
MGADTFTKGLKTFGFSEDVPYEFPIQKSSIANDKLDSDILLADTGYGQGQMQMSPLHLAT
AYTPFVDNGDLVKPTLIKKDSQTADVWHKQVVTKEGAADITKGLKGVVEDERGSAYQPVV
KGITVAGKTGTAELKTSKDDKDGTENGWFVGYDYENKDLLVAMMIQNVQDRGGSHYVVEK
AKKQFQSN

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
P42971

# Drug_Target_1_SwissProt_Name:
PBPC_BACSU

# Drug_Target_1_Synonyms:
PBP 3
PSPB20

# Drug_Target_1_Theoretical_pI:
6.56

# Drug_Target_1_Transmembrane_Regions:
7-23

# Drug_Target_2_Cellular_Location:
Bacterial cell inner membrane
single-pass type II membrane protein

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
3918982	Labia R, Baron P, Masson JM: Binding of latamoxef (moxalactam) and its decarboxylated derivative to Escherichia coli and Pseudomonas aeruginosa penicillin-binding proteins. J Antimicrob Chemother. 1985 Jan;15(1):9-15.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
X02164

# Drug_Target_2_GenBank_ID_Protein:
581194

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
mrcA

# Drug_Target_2_Gene_Sequence:
>2553 bp
GTGAAGTTCGTAAAGTATTTTTTGATCCTTGCAGTCTGTTGCATTCTGCTGGGAGCAGGC
TCGATTTATGGCCTATACCGCTACATCGAGCCACAACTGCCGGATGTGGCGACATTAAAA
GATGTTCGCCTGCAAATTCCGATGCAGATTTACAGCGCCGATGGCGAGCTGATTGCTCAA
TACGGTGAGAAACGTCGTATTCCGGTTACGTTGGATCAAATCCCACCGGAGATGGTGAAA
GCCTTTATCGCGACAGAAGACAGCCGCTTCTACGAGCATCACGGCGTTGACCCGGTGGGG
ATCTTCCGTGCAGCAAGCGTGGCGCTGTTCTCCGGTCACGCGTCACAAGGGGCAAGTACC
ATTACCCAGCAGCTGGCGAGAAACTTCTTCCTCAGTCCAGAACGCACGCTGATGCGTAAG
ATTAAGGAAGTCTTCCTCGCGATTCGCATTGAACAGCTGCTGACGAAAGACGAGATCCTC
GAGCTTTATCTGAACAAGATTTACCTTGGTTACCGCGCCTATGGTGTCGGTGCTGCGGCA
CAAGTCTATTTCGGAAAAACGGTCGACCAACTGACGCTGAACGAAATGGCGGTGATAGCC
GGGCTGCCGAAAGCGCCTTCCACCTTCAACCCGCTCTACTCGATGGATCGTGCCGTCGCG
CGGCGTAACGTCGTGCTGTCGCGGATGCTGGATGAAGGGTATATCACCCAACAACAGTTC
GATCAGACACGCACTGAGGCGATTAACGCTAACTATCACGCGCCGGAGATTGCTTTCTCT
GCGCCGTACCTGAGCGAAATGGTGCGCCAGGAGATGTATAACCGTTATGGCGAAAGTGCC
TATGAAGACGGTTATCGCATTTACACCACCATCACCCGCAAAGTGCAGCAGGCCGCGCAG
CAGGCGGTACGTAATAACGTGCTGGACTACGACATGCGCCACGGCTATCGCGGCCCGGCA
AATGTGCTGTGGAAAGTGGGCGAGTCGGCGTGGGATAACAACAAGATTACCGATACGCTG
AAGGCGCTGCCAACCTATGGTCCGCTGCTGCCTGCCGCAGTCACCAGCGCCAATCCTCAG
CAAGCGACGGCGATGCTGGCGGACGGGTCGACCGTCGCATTGAGTATGGAAGGCGTTCGC
TGGGCGCGTCCTTACCGTTCGGATACTCAGCAAGGACCGACGCCGCGTAAAGTGACCGAT
GTTCTGCAAACGGGTCAGCAAATCTGGGTTCGTCAGGTTGGCGATGCATGGTGGCTGGCA
CAAGTGCCGGAAGTGAACTCGGCGCTGGTGTCGATCAATCCGCAAAACGGTGCCGTTATG
GCGCTGGTCGGTGGCTTTGATTTCAATCAGAGCAAGTTTAACCGCGCCACCCAGGCACTG
CGTCAGGTGGGTTCCAACATCAAACCGTTCCTCTACACCGCGGCGATGGATAAAGGTCTG
ACGCTGGCAAGTATGTTGAACGATGTGCCAATTTCTCGCTGGGATGCAAGTGCCGGTTCT
GACTGGCAGCCGAAGAACTCACCACCGCAGTATGCTGGTCCAATTCGCTTACGTCAGGGG
CTGGGTCAGTCGAAAAACGTGGTGATGGTACGCGCAATGCGGGCGATGGGCGTCGACTAC
GCTGCAGAATATCTGCAACGCTTCGGCTTCCCGGCACAAAACATTGTCCACACCGAATCG
CTGGCGCTGGGTTCAGCGTCCTTCACCCCAATGCAGGTGGCGCGCGGCTACGCGGTCATG
GCGAACGGCGGCTTCCTGGTGGACCCGTGGTTTATCAGCAAAATTGAAAACGATCAGGGC
GGCGTGATTTTCGAAGCGAAACCGAAAGTAGCCTGCCCGGAATGCGATATTCCGGTGATT
TACGGTGATACGCAGAAATCGAACGTGCTGGAAAATAACGATGTTGAAGATGTCGCTATC
TCCCGCGAGCAGCAGAATGTTTCTGTACCAATGCCGCAGCTGGAGCAGGCAAATCAGGCG
TTAGTGGCGAAGACTGGCGCGCAGGAGTACGCACCGCACGTCATCAACACTCCGCTGGCA
TTCCTGATTAAGAGTGCTTTGAACACCAATATCTTTGGTGAGCCAGGCTGGCAGGGTACT
GGCTGGCGTGCAGGTCGTGATTTGCAGCGTCGCGATATCGGCGGGAAAACCGGGACCACT
AACAGTTCGAAAGATGCGTGGTTCTCGGGTTACGGTCCGGGCGTTGTGACCTCGGTCTGG
ATTGGCTTTGATGATCACCGTCGTAATCTCGGTCATACAACGGCTTCCGGAGCGATTAAA
GATCAGATCTCAGGTTACGAAGGCGGTGCCAAGAGTGCCCAGCCTGCATGGGACGCTTAT
ATGAAAGCCGTTCTTGAAGGTGTGCCGGAGCAGCCGCTGACGCCGCCACCGGGTATTGTG
ACGGTGAATATCGATCGCAGCACCGGGCAGTTAGCTAATGGTGGCAACAGCCGCGAAGAG
TATTTCATCGAAGGTACGCAGCCGACACAACAGGCAGTGCACGAGGTGGGAACGACCATT
ATCGATAATGGCGAGGCACAGGAATTGTTCTGA

# Drug_Target_2_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_2_General_References:
3882429	Broome-Smith JK, Edelman A, Yousif S, Spratt BG: The nucleotide sequences of the ponA and ponB genes encoding penicillin-binding protein 1A and 1B of Escherichia coli K12. Eur J Biochem. 1985 Mar 1;147(2):437-46.
3920658	Keck W, Glauner B, Schwarz U, Broome-Smith JK, Spratt BG: Sequences of the active-site peptides of three of the high-Mr penicillin-binding proteins of Escherichia coli K-12. Proc Natl Acad Sci U S A. 1985 Apr;82(7):1999-2003.
7006606	Ishino F, Mitsui K, Tamaki S, Matsuhashi M: Dual enzyme activities of cell wall peptidoglycan synthesis, peptidoglycan transglycosylase and penicillin-sensitive transpeptidase, in purified preparations of Escherichia coli penicillin-binding protein 1A. Biochem Biophys Res Commun. 1980 Nov 17;97(1):287-93.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9841666	Goffin C, Ghuysen JM: Multimodular penicillin-binding proteins: an enigmatic family of orthologs and paralogs. Microbiol Mol Biol Rev. 1998 Dec;62(4):1079-93.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
645

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
93637

# Drug_Target_2_Name:
Penicillin-binding protein 1A

# Drug_Target_2_Number_of_Residues:
850

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00905	Transpeptidase
PF00912	Transgly

# Drug_Target_2_Protein_Sequence:
>Penicillin-binding protein 1A
MKFVKYFLILAVCCILLGAGSIYGLYRYIEPQLPDVATLKDVRLQIPMQIYSADGELIAQ
YGEKRRIPVTLDQIPPEMVKAFIATEDSRFYEHHGVDPVGIFRAASVALFSGHASQGAST
ITQQLARNFFLSPERTLMRKIKEVFLAIRIEQLLTKDEILELYLNKIYLGYRAYGVGAAA
QVYFGKTVDQLTLNEMAVIAGLPKAPSTFNPLYSMDRAVARRNVVLSRMLDEGYITQQQF
DQTRTEAINANYHAPEIAFSAPYLSEMVRQEMYNRYGESAYEDGYRIYTTITRKVQQAAQ
QAVRNNVLDYDMRHGYRGPANVLWKVGESAWDNNKITDTLKALPTYGPLLPAAVTSANPQ
QATAMLADGSTVALSMEGVRWARPYRSDTQQGPTPRKVTDVLQTGQQIWVRQVGDAWWLA
QVPEVNSALVSINPQNGAVMALVGGFDFNQSKFNRATQALRQVGSNIKPFLYTAAMDKGL
TLASMLNDVPISRWDASAGSDWQPKNSPPQYAGPIRLRQGLGQSKNVVMVRAMRAMGVDY
AAEYLQRFGFPAQNIVHTESLALGSASFTPMQVARGYAVMANGGFLVDPWFISKIENDQG
GVIFEAKPKVACPECDIPVIYGDTQKSNVLENNDVEDVAISREQQNVSVPMPQLEQANQA
LVAKTGAQEYAPHVINTPLAFLIKSALNTNIFGEPGWQGTGWRAGRDLQRRDIGGKTGTT
NSSKDAWFSGYGPGVVTSVWIGFDDHRRNLGHTTASGAIKDQISGYEGGAKSAQPAWDAY
MKAVLEGVPEQPLTPPPGIVTVNIDRSTGQLANGGNSREEYFIEGTQPTQQAVHEVGTTI
IDNGEAQELF

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Cell wall formation. Synthesis of cross-linked peptidoglycan from the lipid intermediates. The enzyme has a penicillin-insensitive transglycosylase N-terminal domain (formation of linear glycan strands) and a penicillin-sensitive transpeptidase C-terminal domain (cross-linking of the peptide subunits)

# Drug_Target_2_SwissProt_ID:
P02918

# Drug_Target_2_SwissProt_Name:
PBPA_ECOLI

# Drug_Target_2_Synonyms:
DD-transpeptidase
EC 2.4.2.-
EC 3.4.-.-
PBP-1a
PBP1a
Penicillin-sensitive transpeptidase
Peptidoglycan TGase

# Drug_Target_2_Theoretical_pI:
6.53

# Drug_Target_2_Transmembrane_Regions:
6-26

# Drug_Target_3_Cellular_Location:
Bacterial cell inner membrane
single-pass type II membrane protein

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
3918982	Labia R, Baron P, Masson JM: Binding of latamoxef (moxalactam) and its decarboxylated derivative to Escherichia coli and Pseudomonas aeruginosa penicillin-binding proteins. J Antimicrob Chemother. 1985 Jan;15(1):9-15.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
X02163

# Drug_Target_3_GenBank_ID_Protein:
42468

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
mrcB

# Drug_Target_3_Gene_Sequence:
>2535 bp
ATGGCCGGGAATGACCGCGAGCCAATTGGACGCAAAGGGAAACCGACGCGTCCGGTCAAA
CAAAAGGTAAGCCGTCGTCGTTACGAAGATGACGATGATTACGACGATTATGATGACTAT
GAGGATGAAGAACCGATGCCGCGCAAAGGTAAGGGCAAAGGCAAAGGGCGTAAGCCTCGT
GGCAAACGCGGCTGGCTATGGCTACTGCTAAAACTGGCTATCGTTTTTGCCGTGCTGATC
GCCATTTACGGCGTTTATCTCGATCAAAAAATTCGTAGCCGTATTGATGGCAAGGTCTGG
CAACTCGCTGCGGCAGTTTATGGCCGAATGGTCAATCTTGAGCCAGACATGACCATCAGC
AAGAACGAGATGGTGAAGCTGCTGGAGGCGACCCAGTATCGTCAGGTGTCGAAAATGACC
CGTCCTGGCGAATTTACCGTGCAGGCCAACAGCATTGAGATGATTCGCCGTCCGTTTGAT
TTCCCGGACAGTAAAGAAGGACAGGTGCGCGCGCGTCTGACCTTTGATGGCGATCATCTG
GCGACGATCGTCAATATGGAGAACAACCGTCAGTTCGGTTTCTTCCGTCTTGATCCGCGT
CTGATCACCATGATCTCTTCGCCAAACGGTGAGCAGCGTCTGTTTGTGCCGCGCAGTGGT
TTCCCGGATTTGCTGGTGGATACTTTGCTGGCGACAGAAGACCGTCATTTTTACGAGCAT
GATGGAATCAGTCTCTACTCAATCGGACGTGCGGTGCTGGCAAACCTGACCGCCGGACGC
ACGGTACAGGGTGCGAGTACGCTGACGCAACAGCTGGTGAAAAACCTGTTCCTCTCCAGC
GAGCGTTCTTACTGGCGTAAAGCGAACGAAGCTTACATGGCGCTGATCATGGACGCGCGT
TACAGCAAAGACCGTATTCTTGAGCTGTATATGAACGAGGTGTATCTCGGTCAGAGCGGC
GACAACGAAATCCGCGGCTTCCCGCTGGCAAGCTTGTATTACTTTGGTCGCCCGGTAGAA
GAGCTAAGCCTCGACCAGCAGGCGCTGTTAGTCGGTATGGTGAAAGGGGCGTCCATCTAC
AACCCGTGGCGTAACCCAAAACTGGCGCTGGAGCGACGTAATCTGGTGCTGCGTCTGCTG
CAACAGCAACAGATTATTGATCAAGAACTCTATGACATGTTGAGTGCCCGTCCGCTGGGG
GTTCAGCCGCGCGGTGGGGTGATCTCTCCTCAGCCAGCCTTTATGCAACTGGTGCGTCAG
GAGCTGCAGGCAAAACTGGGCGATAAGGTAAAAGATCTCTCCGGCGTGAAGATCTTCACT
ACCTTTGACTCGGTGGCCCAGGACGCGGCAGAAAAAGCCGCCGTGGAAGGCATTCCGGCA
CTGAAGAAACAGCGTAAGTTGAGCGATCTTGAAACTGCGATTGTGGTCGTCGACCGCTTT
AGTGGTGAAGTTCGTGCGATGGTCGGAGGTTCTGAGCCGCAGTTTGCGGGCTACAACCGT
GCGATGCAGGCGCGTCGTTCGATTGGTTCCCTTGCAAAACCAGCGACTTATCTGACGGCC
TTAAGCCAGCCGAAAATCTATCGTCTGAATACGTGGATTGCGGATGCGCCAATTGCGCTG
CGTCAGCCGAATGGCCAGGTCTGGTCACCGCAGAATGATGACCGTCGTTATAGCGAAAGC
GGCAGAGTGATGCTGGTGGATGCGTTGACCCGTTCGATGAACGTGCCGACGGTAAATCTG
GGGATGGCGCTGGGGCTGCCTGCGGTTACGGAGACCTGGATTAAACTGGGCGTACCGAAA
GATCAGTTGCATCCGGTTCCGGCAATGCTGCTGGGGGCGTTGAACTTAACGCCAATCGAA
GTGGCGCAGGCATTCCAGACCATCGCCAGCGGTGGTAACCGTGCACCGCTTTCTGCGCTG
CGTTCGGTAATCGCGGAAGATGGCAAAGTGCTGTATCAGAGCTTCCCGCAGGCGGAACGC
GCTGTTCCGGCGCAGGCGGCGTATCTGACACTATGGACCATGCAGCAGGTGGTACAACGC
GGTACGGGTCGTCAGCTTGGGGCGAAATACCCGAACCTGCATCTGGCAGGGAAAACAGGG
ACTACCAACAATAACGTAGATACCTGGTTTGCGGGCATTGACGGCAGCACGGTGACCATC
ACCTGGGTCGGCCGTGATAACAACCAGCCGACCAAACTGTATGGTGCCAGCGGGGCAATG
TCGATTTATCAGCGTTATCTGGCTAACCAGACGCCAACGCCGCTGAATCTTGTTCCGCCA
GAAGATATTGCAGATATGGGCGTGGACTACGACGGCAACTTTGTTTGCAGCGGTGGCATG
CGTATCTTGCCGGTCTGGACCAGCGATCCGCAATCGCTGTGCCAGCAGAGCGAGATGCAG
CAGCAGCCGTCAGGCAATCCGTTTGATCAGTCTTCTCAGCCGCAGCAACAGCCGCAACAG
CAACCTGCTCAGCAAGAGCAGAAAGACAGCGACGGTGTAGCCGGTTGGATCAAGGATATG
TTTGGTAGTAATTAA

# Drug_Target_3_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_3_General_References:
10037771	Vollmer W, von Rechenberg M, Holtje JV: Demonstration of molecular interactions between the murein polymerase PBP1B, the lytic transglycosylase MltA, and the scaffolding protein MipA of Escherichia coli. J Biol Chem. 1999 Mar 5;274(10):6726-34.
10564478	Terrak M, Ghosh TK, van Heijenoort J, Van Beeumen J, Lampilas M, Aszodi J, Ayala JA, Ghuysen JM, Nguyen-Disteche M: The catalytic, glycosyl transferase and acyl transferase modules of the cell wall peptidoglycan-polymerizing penicillin-binding protein 1b of Escherichia coli. Mol Microbiol. 1999 Oct;34(2):350-64.
1885547	Zijderveld CA, Aarsman ME, den Blaauwen T, Nanninga N: Penicillin-binding protein 1B of Escherichia coli exists in dimeric forms. J Bacteriol. 1991 Sep;173(18):5740-6.
3330753	Edelman A, Bowler L, Broome-Smith JK, Spratt BG: Use of a beta-lactamase fusion vector to investigate the organization of penicillin-binding protein 1B in the cytoplasmic membrane of Escherichia coli. Mol Microbiol. 1987 Jul;1(1):101-6.
3882429	Broome-Smith JK, Edelman A, Yousif S, Spratt BG: The nucleotide sequences of the ponA and ponB genes encoding penicillin-binding protein 1A and 1B of Escherichia coli K12. Eur J Biochem. 1985 Mar 1;147(2):437-46.
3920658	Keck W, Glauner B, Schwarz U, Broome-Smith JK, Spratt BG: Sequences of the active-site peptides of three of the high-Mr penicillin-binding proteins of Escherichia coli K-12. Proc Natl Acad Sci U S A. 1985 Apr;82(7):1999-2003.
8202364	Fujita N, Mori H, Yura T, Ishihama A: Systematic sequencing of the Escherichia coli genome: analysis of the 2.4-4.1 min (110,917-193,643 bp) region. Nucleic Acids Res. 1994 May 11;22(9):1637-9.
8645198	Wang CC, Schultz DE, Nicholas RA: Localization of a putative second membrane association site in penicillin-binding protein 1B of Escherichia coli. Biochem J. 1996 May 15;316 ( Pt 1):149-56.
9244263	Lefevre F, Remy MH, Masson JM: Topographical and functional investigation of Escherichia coli penicillin-binding protein 1b by alanine stretch scanning mutagenesis. J Bacteriol. 1997 Aug;179(15):4761-7.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9841666	Goffin C, Ghuysen JM: Multimodular penicillin-binding proteins: an enigmatic family of orthologs and paralogs. Microbiol Mol Biol Rev. 1998 Dec;62(4):1079-93.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
543

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
94294

# Drug_Target_3_Name:
Penicillin-binding protein 1B

# Drug_Target_3_Number_of_Residues:
844

# Drug_Target_3_PDB_ID:
Not Available

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00905	Transpeptidase
PF00912	Transgly

# Drug_Target_3_Protein_Sequence:
>Penicillin-binding protein 1B
MAGNDREPIGRKGKPTRPVKQKVSRRRYEDDDDYDDYDDYEDEEPMPRKGKGKGKGRKPR
GKRGWLWLLLKLAIVFAVLIAIYGVYLDQKIRSRIDGKVWQLPAAVYGRMVNLEPDMTIS
KNEMVKLLEATQYRQVSKMTRPGEFTVQANSIEMIRRPFDFPDSKEGQVRARLTFDGDHL
ATIVNMENNRQFGFFRLDPRLITMISSPNGEQRLFVPRSGFPDLLVDTLLATEDRHFYEH
DGISLYSIGRAVLANLTAGRTVQGASTLTQQLVKNLFLSSERSYWRKANEAYMALIMDAR
YSKDRILELYMNEVYLGQSGDNEIRGFPLASLYYFGRPVEELSLDQQALLVGMVKGASIY
NPWRNPKLALERRNLVLRLLQQQQIIDQELYDMLSARPLGVQPRGGVISPQPAFMQLVRQ
ELQAKLGDKVKDLSGVKIFTTFDSVAQDAAEKAAVEGIPALKKQRKLSDLETAIVVVDRF
SGEVRAMVGGSEPQFAGYNRAMQARRSIGSLAKPATYLTALSQPKIYRLNTWIADAPIAL
RQPNGQVWSPQNDDRRYSESGRVMLVDALTRSMNVPTVNLGMALGLPAVTETWIKLGVPK
DQLHPVPAMLLGALNLTPIEVAQAFQTIASGGNRAPLSALRSVIAEDGKVLYQSFPQAER
AVPAQAAYLTLWTMQQVVQRGTGRQLGAKYPNLHLAGKTGTTNNNVDTWFAGIDGSTVTI
TWVGRDNNQPTKLYGASGAMSIYQRYLANQTPTPLNLVPPEDIADMGVDYDGNFVCSGGM
RILPVWTSDPQSLCQQSEMQQQPSGNPFDQSSQPQQQPQQQPAQQEQKDSDGVAGWIKDM
FGSN

# Drug_Target_3_Reaction:
[GlcNAc-(1->4)-Mur2Ac(oyl-L-Ala-gamma-D-Glu-L-Lys-D-Ala-D-Ala)]n- diphosphoundecaprenol + GlcNAc-(1->4)-Mur2Ac(oyl-L-Ala-gamma-D-Glu-L-Lys-D-Ala-D-Ala)- diphosphoundecaprenol = [GlcNAc-(1->4)-Mur2Ac(oyl-L-Ala-gamma-D-Glu-L-Lys-D-Ala-D-Ala)]n+1- diphosphoundecaprenol + undecaprenyl diphosphate

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Cell wall formation. Synthesis of cross-linked peptidoglycan from the lipid intermediates. The enzyme has a penicillin-insensitive transglycosylase N-terminal domain (formation of linear glycan strands) and a penicillin-sensitive transpeptidase C-terminal domain (cross-linking of the peptide subunits)

# Drug_Target_3_SwissProt_ID:
P02919

# Drug_Target_3_SwissProt_Name:
PBPB_ECOLI

# Drug_Target_3_Synonyms:
EC 2.4.1.129
EC 3.4.-.-
Murein polymerase
PBP-1b
PBP1b
Penicillin- sensitive transpeptidase
Peptidoglycan TGase
Peptidoglycan glycosyltransferase

# Drug_Target_3_Theoretical_pI:
9.46

# Drug_Target_3_Transmembrane_Regions:
64-87

# Drug_Target_4_Cellular_Location:
Periplasm (Potential)

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
3918982	Labia R, Baron P, Masson JM: Binding of latamoxef (moxalactam) and its decarboxylated derivative to Escherichia coli and Pseudomonas aeruginosa penicillin-binding proteins. J Antimicrob Chemother. 1985 Jan;15(1):9-15.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
Not Available

# Drug_Target_4_GenBank_ID_Gene:
X59460

# Drug_Target_4_GenBank_ID_Protein:
41216

# Drug_Target_4_GeneCard_ID:
Not Available

# Drug_Target_4_Gene_Name:
dacB

# Drug_Target_4_Gene_Sequence:
>1434 bp
ATGCGATTTTCCAGATTTATCATCGGATTGACCAGCTGTATAGCGTTCAGTGTTCAGGCC
GCAAATGTTGATGAGTACATTACTCAACTCCCCGCTGGTGCCAACCTTGCCCTGATGGTG
CAAAAAGTCGGCGCGTCGGCCCCCGCTATTGATTACCACAGTCAGCAGATGGCGCTGCCT
GCCAGTACCCAGAAAGTGATTACTGCGCTGGCGGCGTTGATTCAACTCGGCCCCGATTTT
CGTTTTACCACGACGCTTGAAACCAAAGGCAATGTGGAAAACGGCGTACTTAAGGGTGAC
TTAGTGGCGCGATTTGGTGCCGATCCGACGTTAAAACGTCAGGATATTCGCAATATGGTC
GCGACTTTGAAAAAATCTGGCGTCAACCAAATCGATGGCAATGTGTTGATAGATACCTCC
ATTTTCGCCAGCCACGATAAAGCCCCCGGCTGGCCATGGAATGACATGACACAATGCTTT
AGCGCTCCGCCTGCCGCCGCCATAGTTGACCGCAACTGTTTCTCCGTCTCGCTCTACAGT
GCCCCAAAGCCTGGTGATATGGCTTTTATACGCGTGGCATCTTATTACCCCGTTACGATG
TTCAGCCAGGTACGCACCCTCCCCCGTGGTTCTGCCGAAGCGCAATACTGCGAACTGGAT
GTGGTGCCAGGCGACCTGAACCGCTTTACGCTGACGGGATGCCTGCCACAACGTTCTGAG
CCGCTCCCGTTGGCTTTTGCCGTGCAGGATGGAGCCAGCTATGCCGGTGCAATTCTGAAA
GATGAGTTAAAACAGGCGGGTATCACCTGGAGCGGAACACTGCTGCGCCAGACTCAGGTT
AACGAACCTGGAACGGTAGTTGCCAGTAAACAGTCGGCCCCGCTGCACGATCTGCTTAAG
ATTATGCTGAAAAAGTCGGACAACATGATCGCCGATACGGTTTTCCGCATGATAGGCCAT
GCGCGCTTCAATGTGCCTGGAACATGGCGGGCCGGGTCGGACGCCGTGCGTCAGATCCTG
CGCCAGCAAGCCGGTGTCGATATTGGAAACACCATTATTGCCGATGGTTCAGGGCTTTCG
CGGCATAACCTGATTGCCCCCGCCACCATGATGCAGGTGCTGCAATACATTGCCCAACAC
GACAATGAACTTAACTTTATCTCCATGCTGCCGCTGGCGGGCTATGACGGCTCTTTGCAG
TACCGTGCAGGTCTGCATCAGGCGGGCGTGGATGGAAAAGTCTCAGCGAAAACCGGTTCG
TTGCAGGGGGTATATAACCTGGCGGGATTCATTACCACAGCGAGCGGGCAACGAATGGCG
TTTGTGCAATATCTTTCTGGCTATGCAGTAGAACCTGCGGATCAGCGTAATCGCCGTATT
CCGTTAGTGCGTTTTGAAAGCCGTTTGTATAAAGATATTTATCAGAACAATTAG

# Drug_Target_4_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_4_General_References:
2040429	Mottl H, Terpstra P, Keck W: Penicillin-binding protein 4 of Escherichia coli shows a novel type of primary structure among penicillin-interacting proteins. FEMS Microbiol Lett. 1991 Mar 1;62(2-3):213-20.
2046551	Korat B, Mottl H, Keck W: Penicillin-binding protein 4 of Escherichia coli: molecular cloning of the dacB gene, controlled overexpression, and alterations in murein composition. Mol Microbiol. 1991 Mar;5(3):675-84.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_4_HGNC_ID:
Not Available

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
819

# Drug_Target_4_Locus:
Not Available

# Drug_Target_4_Molecular_Weight:
51799

# Drug_Target_4_Name:
Penicillin-binding protein 4

# Drug_Target_4_Number_of_Residues:
477

# Drug_Target_4_PDB_ID:
Not Available

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF02113	Peptidase_S13

# Drug_Target_4_Protein_Sequence:
>Penicillin-binding protein 4 precursor
MRFSRFIIGLTSCIAFSVQAANVDEYITQLPAGANLALMVQKVGASAPAIDYHSQQMALP
ASTQKVITALAALIQLGPDFRFTTTLETKGNVENGVLKGDLVARFGADPTLKRQDIRNMV
ATLKKSGVNQIDGNVLIDTSIFASHDKAPGWPWNDMTQCFSAPPAAAIVDRNCFSVSLYS
APKPGDMAFIRVASYYPVTMFSQVRTLPRGSAEAQYCELDVVPGDLNRFTLTGCLPQRSE
PLPLAFAVQDGASYAGAILKDELKQAGITWSGTLLRQTQVNEPGTVVASKQSAPLHDLLK
IMLKKSDNMIADTVFRMIGHARFNVPGTWRAGSDAVRQILRQQAGVDIGNTIIADGSGLS
RHNLIAPATMMQVLQYIAQHDNELNFISMLPLAGYDGSLQYRAGLHQAGVDGKVSAKTGS
LQGVYNLAGFITTASGQRMAFVQYLSGYAVEPADQRNRRIPLVRFESRLYKDIYQNN

# Drug_Target_4_Reaction:
Preferential cleavage: (Ac)2-L-Lys-D-Ala!D-Ala. Also transpeptidation of peptidyl-alanyl moieties that are N-acyl substituents of D-alanine INHIBITOR Penicillin; beta-Lactam antibiotics

# Drug_Target_4_Signals:
1-20

# Drug_Target_4_Specific_Function:
Not involved in transpeptidation but exclusively catalyzes a DD-carboxypeptidase and DD-endopeptidase reaction

# Drug_Target_4_SwissProt_ID:
P24228

# Drug_Target_4_SwissProt_Name:
DACB_ECOLI

# Drug_Target_4_Synonyms:
D-alanyl-D-alanine-endopeptidase
DD- carboxypeptidase
DD-peptidase
EC 3.4.16.4
EC 3.4.99.-
PBP-4
Penicillin-binding protein 4 precursor

# Drug_Target_4_Theoretical_pI:
9.02

# Drug_Target_4_Transmembrane_Regions:
None

#END_DRUGCARD DB04570
